Q2 EPS Forecast for Gain Therapeutics Decreased by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Stock analysts at Roth Capital cut their Q2 2025 earnings per share estimates for shares of Gain Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.17). The consensus estimate for Gain Therapeutics' current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.71) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.84) EPS.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.16).

Other research analysts also recently issued research reports about the company. Scotiabank assumed coverage on Gain Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday. Finally, Chardan Capital reissued a "buy" rating and set a $6.00 price target on shares of Gain Therapeutics in a research note on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Gain Therapeutics has an average rating of "Buy" and a consensus price target of $8.20.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX traded up $0.01 during trading on Monday, reaching $1.80. The company had a trading volume of 72,466 shares, compared to its average volume of 310,559. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $3.19. The stock has a market cap of $53.20 million, a PE ratio of -1.64 and a beta of 0.17. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The business's 50 day moving average price is $1.90 and its 200-day moving average price is $2.00.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kovitz Investment Group Partners LLC bought a new stake in Gain Therapeutics in the first quarter valued at approximately $91,000. Dauntless Investment Group LLC bought a new position in shares of Gain Therapeutics during the first quarter worth about $240,000. Bridgeway Capital Management LLC bought a new position in Gain Therapeutics in the fourth quarter valued at $65,000. Northern Trust Corp grew its holdings in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after acquiring an additional 39,642 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Gain Therapeutics in the 4th quarter valued at about $198,000. Institutional investors own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.